Brinker Capital Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Brinker Capital Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,302	Closed	-$423K	–	1468
2021 Q3	$423K	Hold	2,302	–	–	0.01%	1028
2021 Q2	$423K	Sell	2,302 -1,256	-35%	-$216K	0.01%	1087
2021 Q1	$544K	Sell	3,558 -7,060	-66%	-$1.09M	0.01%	879
2020 Q4	$1.66M	Sell	10,618 -1,822	-15%	-$234K	0.03%	591
2020 Q3	$1.42M	Buy	+12,440	New	+$1.34M	0.02%	580
2019 Q4	–	Sell	-79	Closed	-$8K	–	892
2019 Q3	$8K	Buy	+79	New	+$8.9K	﹤0.01%	597
2016 Q4	–	Sell	-2	Closed	–	–	679
2016 Q3	$0	Buy	+2	New	+$257	﹤0.01%	649
2016 Q1	–	Sell	-7	Closed	-$1K	–	729
2015 Q4	$1K	Hold	7	–	–	﹤0.01%	554
2015 Q3	$1K	Buy	+7	New	+$1.28K	﹤0.01%	444

Other funds holding ALXN

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

Brinker Capital Investments's ALXN Position: Q4 2021 in Review

Brinker Capital Investments sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 2,302 shares — an estimated $423K sold.

Brinker Capital Investments first reported a position in ALXN in Q3 2015 and held it in 9 quarters. The position peaked at $1.66M in Q4 2020. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.

Brinker Capital Investments reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Brinker Capital Investments sold 2,302 Alexion Pharmaceuticals shares in Q4 2021, an estimated $423K.
Brinker Capital Investments first reported a position in Alexion Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Brinker Capital Investments's Alexion Pharmaceuticals position peaked at $1.66M in Q4 2020.
2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.

Based on Brinker Capital Investments's 13F filing for Q4 2021, filed 8 Feb 2022.